Total trials
507
Active
40
Phase 3
95
Total enrollment
290,256
Pipeline matrix
Showing 34 of 34 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tofersen | — | — | 7 | ||||
| Felzartamab | — | — | — | — | 5 | ||
| Litifilimab | — | — | — | — | 5 | ||
| Omaveloxolone | — | — | 15 | ||||
| Diroximel Fumarate | — | — | — | 8 | |||
| Salanersen | — | — | — | — | — | 3 | |
| dimethyl fumarate | — | 38 | |||||
| Nusinersen | — | 16 | |||||
| Fingolimod | — | — | — | 3 | |||
| BIIB017 | — | — | — | 6 | |||
| BIIB059 | — | — | — | 4 | |||
| Interferon beta type 1a | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Standard of Care IST | — | — | — | — | — | 1 | |
| Diranersen | — | — | — | — | 2 | ||
| BIIB145 | — | — | — | — | — | 1 | |
| BIIB142 | — | — | — | — | — | 1 | |
| BIIB144 | — | — | — | — | — | 1 | |
| BIIB115 | — | — | — | — | — | 1 | |
| natalizumab | — | 44 | |||||
| Zuranolone | — | — | — | — | 3 | ||
| peginterferon beta-1a | — | — | 10 | ||||
| glatiramer acetate | — | — | — | 5 | |||
| Avonex | — | — | 5 | ||||
| Tysabri | — | — | — | — | — | 3 | |
| Nusinersen Sodium | — | — | — | — | — | 2 | |
| Interferon Beta | — | — | — | — | 2 | ||
| Disease-Modifying Therapies | — | — | — | — | — | 1 | |
| Alemtuzumab | — | — | — | — | — | 1 | |
| Ocrelizumab | — | — | — | — | — | 1 | |
| Ofatumumab | — | — | — | — | — | 1 | |
| Ozanimod | — | — | — | — | — | 1 | |
| Ponesimod | — | — | — | — | — | 1 | |
| Siponimod | — | — | — | — | — | 1 |
Next readouts
- 2025-09-30
- 2026-03-11
- 2026-07-31
- 2026-08-06
- 2026-08-24
- 2026-09-27
- 2026-09-30
- 2026-10-20
- 2026-10-31
- 2026-12-01
Top conditions
- Multiple Sclerosis83
- Healthy43
- Relapsing-Remitting Multiple Sclerosis40
- Healthy Volunteer26
- Multiple Sclerosis, Relapsing-Remitting22
- Healthy Volunteers22
- Spinal Muscular Atrophy13
- Rheumatoid Arthritis13
Frequently asked questions about Biogen
- How many clinical trials does Biogen have on ClinicalTrials.gov?
- Biogen is listed as the lead sponsor on 507 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Biogen's trials are in Phase 3?
- 95 of Biogen's trials are in Phase 3, spread across 34 active drug programs.
- What therapeutic areas does Biogen focus on?
- Biogen's most-studied conditions on ClinicalTrials.gov are Multiple Sclerosis, Healthy, Relapsing-Remitting Multiple Sclerosis, Healthy Volunteer, Multiple Sclerosis, Relapsing-Remitting.
- When are Biogen's next clinical trial readouts?
- Biogen has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old”, expected around 2025-09-30.